来自微生物群的溶解脂胆可以通过抑制铁化来缓解阿尔茨海默氏病的病理
Xu Zha1, Xicheng Liu1, Mengping Wei2
1School of Basic Medical Sciences, Beijing Key Laboratory of Neural Regeneration and Repair & Beijing Key Laboratory for Tumor Invasion and Metastasis, Beijing Laboratory of Oral Health, Capital Medical University, Beijing, China; State Key Laboratory of Neurology and Oncology Drug Development, Nanjing, China.
Cell metabolism
|November 7, 2024
概括
研究人员在阿尔茨海默氏症 (AD) 中发现了肠-大脑连接. 恢复肠道细菌 Bacteroides ovatus 和其代谢物 lysophosphatidylcholine (LPC) 减少了粉样蛋白斑块,并改善了小鼠的认知能力.
科学领域:
- 神经科学是一个神经科学.
- 微生物学 微生物学
- 胃肠病学 胃肠病学
背景情况:
- 阿尔茨海默病 (AD) 是神经退行的主要原因,治疗选择有限.
- 肠道微生物群对大脑健康和神经退行性疾病的作用是一个新兴的研究领域.
- 识别特定的微生物和代谢点对于开发新的AD干预措施至关重要.
研究的目的:
- 为了研究在阿尔茨海默病的肠道-微生物组-大脑轴.
- 为了确定与粉样β (Aβ) 负担相关的特定肠道微生物变化.
- 探索肠道微生物群或其代谢物的治疗潜力,以改善AD病理.
主要方法:
- 利用了阿尔茨海默病的5xFAD小鼠模型.
- 分析了肠道微生物组成 (Clostridium, Bacteroides) 和Aβ负载.
- 给小鼠使用 Bacteroides ovatus 或其代谢物溶酸胆 (LPC).
- 研究了涉及GPR119,ACSL4和铁亡的分子机制.
- 分析了来自AD患者的人类便和血清样本.
主要成果:
- 在5xFAD小鼠中,增加的Clostridium和减少的Bacteroides丰度与更高的Aβ负担相关.
- 用B. ovatus或LPC治疗显著降低了Aβ负载并改善了认知功能.
- 发现LPC通过GPR119起作用,抑制ACSL4的表达和抑制铁亡.
- 在人类AD患者中观察到细菌体和LPC水平的降低.
- 确定了一种特定的肠-微生物组-大脑通路,调节AD.
结论:
- 肠道细菌B. ovatus及其代谢物LPC显示出对阿尔茨海默病的治疗潜力.
- 准肠道微生物组或特定代谢物提供了一个新的AD预防和治疗策略.
- 已识别的LPC-GPR119-ACSL4通路提供了肠道失调和AD病理之间的机械联系.
相关概念视频
01:26Alzheimer's Disease: Overview
448
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
448
01:22Alzheimer's Disease: Treatment
165
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
165
01:22Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K
03:03Amyloid Fibrils
9.3K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
9.3K